Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Circulating microRNA of metastatic human melanoma model

ABSTRACT: Circulating microRNA enriched in plasma small extracellular vesicles profiling in a preclinical model of metastatic human melanoma in the mouse brain

PROVIDER: PRJEB36207 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	ERR3829793.fastq.gz	Fastqsanger.gz
	ERR3829784.fastq.gz	Fastqsanger.gz
	ERR3829794.fastq.gz	Fastqsanger.gz
	ERR3829795.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomic and transcriptomic evolution

Project description:Extracellular vesicles (EVs) secreted by tumors are abundant in plasma, but their potential for multi-omic profiling remains widely unexplored. Here, we pursued next-generation sequencing of circulating EV-DNA and EV-RNA in metastatic prostate cancer (mPC), using a range of in-vitro and in-vivo models, validating our findings in 35 mPC patients with longitudinal samples collected during androgen receptor signaling inhibitor (ARSI) therapy. EV-DNA copy-number (CN) profiles matched same-patient biopsies and ctDNA (p<0.001) and EV-DNA tumor fraction (TF) associated with shorter time to progression. We developed a novel approach for studying mRNA in circulating EVs (RExCuE), showing high correlation between EV-RNA and tumor biopsies (r>0.7, p<0.001). EV-RNAseq signatures at 4 weeks of therapy associated with clinical responses. Last, we derived a specific signature of ARSI response in EV-RNA in vivo that predicted response to therapy. In conclusion, EV profiling enables the study of mPC evolution at transcriptomics level in liquid biopsies.

2024-06-30 | GSE221709 | GEO

Use of lymph-circulating extracellular vesicles as surrogate markers of melanoma progression and BRAFV600E mutation

Project description:Liquid biopsies are becoming imperative on early patient diagnosis, prognosis and evaluation of residual disease. The use of circulating extracellular vesicles (EVs) as surrogate markers of tumor progression could be a powerful tool in the clinical setting. EVs in plasma have emerged as a non-invasive option to detect metastatic outcome, however sensitivity is low. Here we have characterized the lymph obtained after postoperative lymphadenectomy as a novel biological fluid enriched in EVs. Our proteomic profiling and BRAFV600E/K status determination demonstrate for the first time that EVs from the lymph of melanoma patients are enriched in melanoma-associated proteins and are useful for BRAF mutations detection. Melanoma oncogenic pathways, immunomodulation and platelet activating proteins are enriched in lymph-derived exosomes from patients with distal lymph node spread compared to local/early spreading. Furthermore, patients positive for BRAFV600E mutation on lymph-circulating vesicles had a shorter time of relapse. These data encourage the analysis of lymph-circulating EVs for detection of residual disease and recurrence.

2019-03-13 | PXD012042 | Pride

Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomic and transcriptomic evolution

Project description:Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomic and transcriptomic evolution

| PRJNA915409 | ENA

Use of lymph-circulating extracellular vesicles as surrogates of melanoma progression markers and BRAFV600E mutation.

2021-02-26 | PXD009505 | Pride

Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis

Project description:Brain metastases are critical for outcomes and quality of life in almost 50% of oncological patients, generally associated with a poor short-term prognosis. Early or preventive diagnosis of this complication represents an unmet need. There is a necessity of discovering new biomarkers that could aid to predict disease outcome. In this study, we analyzed plasma circulating extracellular vesicles (EVs) from a cohort of 92 patients with different solid tumors (lung, breast, kidney cancer and melanoma) and found that newly diagnosed patients with brain metastases presented lower number of circulating particles and a higher protein concentration in small extracellular vesicles (sEVs) compared to patients without brain metastases and healthy controls. Out of all groups analyzed, melanoma patients with brain metastases presented decreased STAT3 activation and increased PD-L1 levels in circulating sEVs compared to patients without central nervous system metastases. The data presented in this work suggest that circulating sEVs may represent the immunosuppressive status of newly diagnosed brain metastases characterized by the reduced phospho-STAT3 (pSTAT3) and increased PD-L1, although the origin of these molecules found in circulating sEVs remains to be uncovered.

2022-05-08 | PXD032767 | Pride

Circulating microRNA profile in aortic stenosis

Project description:We compared the circulating plasma microRNA profile in EDTA plasma in patients with aortic stenosis to a control group.

2015-08-25 | E-MTAB-2785 | biostudies-arrayexpress

Identification of microRNA Biomarkers Simultaneously Expressed in Circulating Extracellular Vesicles and Atherosclerotic Plaques

Project description:microRNA Biomarkers Expressed in Circulating Extracellular Vesicles and Atherosclerotic Plaques

| PRJEB72543 | ENA

A MicroRNA Next-Generation-Sequencing Discovery Assay (miND) For Genome-Scale and Absolute Quantitation of Circulating MicroRNA Biomarkers

Project description:The plasma levels of tissue-specific microRNAs can be used as prognostic and diagnostic biomarkers for chronic and acute diseases. Thereby, the combination of diverse miRNAs into biomarker signatures using multivariate statistics seems especially powerful in view to tissue and condition specific miRNA shedding into the plasma. Although Next-Generation Sequencing (NGS) technology enables to analyse circulating microRNAs on a genome-scale level, it suffers from potential biases (e.g. adapter ligation bias) and lacks absolute transcript quantitation. In order to develop a robust NGS discovery assay for genome-scale quantitation of circulating microRNAs we first evaluated the sensitivity, repeatability and ligation bias of four commercially available small RNA library preparation protocols. The protocol from RealSeq Biosciences was selected based on its performance and usability, and coupled with a novel panel of exogenous small RNA spike-in controls to enable absolute quantitation and ensure comparability of data across independent NGS experiments. The established MicroRNA Next-Generation-Sequencing Discovery Assay (miND) was validated for its relative accuracy, precision, analytical measurement range and sequencing bias and was considered fit-for-purpose for microRNA biomarker discovery. Summarized, all these criteria were met and thus our analytical platform is considered fit-for-purpose for microRNA biomarker discovery from plasma, serum, cerebrospinal fluid (CSF), synovial fluid (SF), or extracellular vesicles (EV) extracted from cell culture medium in the setting of any diagnostic, prognostic or patient stratification need.

2022-01-20 | GSE189930 | GEO

Profiling of LNCaP-SL after circulating small extracellular vesicles treatment

Project description:RNA was isolated from LNCaP-SL after 24 hours of circulating small extracellular vesicles (csEV) single dose treatment (1×10^10 particles/mL).

2021-04-25 | GSE173246 | GEO

Mitochondrial RNA in Alzheimer’s Disease Circulating Extracellular Vesicles

Project description:Mitochondrial RNA in Alzheimer’s Disease Circulating Extracellular Vesicles

| PRJNA644390 | ENA